Theralase Technologies (FRA:TTX) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TTX Theralase Technologies Inc FRA:TTX
51 GF Score
Price €0.11
GF Value €0.10
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Theralase Technologies Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Theralase Technologies  (FRA:TTX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Theralase Technologies Cyclically Adjusted PS Ratio Related Terms


Theralase Technologies Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Theralase Technologies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralase Technologies Cyclically Adjusted PS Ratio Chart

Theralase Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.86 18.73 11.06 20.25 12.57

Theralase Technologies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.56 13.13 11.00 19.25 19.71

FRA:TTX vs ABT, SYK, MDT: Cyclically Adjusted PS Ratio Comparison

For the Medical Devices subindustry, Theralase Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralase Technologies Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's Cyclically Adjusted PS Ratio falls into.


FRA:TTX
51GF Score
Theralase Technologies Inc FRA:TTX
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theralase Technologies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Theralase Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Theralase Technologies's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/133.5265*133.5265
=0.000

Current CPI (Jun. 2026) = 133.5265.

Theralase Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.002 101.765 0.003
201612 0.004 101.449 0.005
201703 0.003 102.634 0.004
201706 0.003 103.029 0.004
201709 0.002 103.345 0.003
201712 0.005 103.345 0.006
201803 0.002 105.004 0.003
201806 0.002 105.557 0.003
201809 0.002 105.636 0.003
201812 0.002 105.399 0.003
201903 0.001 106.979 0.001
201906 0.001 107.690 0.001
201909 0.001 107.611 0.001
201912 0.001 107.769 0.001
202003 0.000 107.927 0.000
202006 0.001 108.401 0.001
202009 0.001 108.164 0.001
202012 0.001 108.559 0.001
202103 0.000 110.298 0.000
202106 0.001 111.720 0.001
202109 0.000 112.905 0.000
202112 0.001 113.774 0.001
202203 0.001 117.646 0.001
202206 0.001 120.806 0.001
202209 0.001 120.648 0.001
202212 0.001 120.964 0.001
202303 0.001 122.702 0.001
202306 0.001 124.203 0.001
202309 0.001 125.230 0.001
202312 0.001 125.072 0.001
202403 0.001 126.258 0.001
202406 0.000 127.522 0.000
202409 0.001 127.285 0.001
202412 0.001 127.364 0.001
202503 0.000 129.181 0.000
202506 0.001 129.892 0.001
202509 0.001 130.287 0.001
202512 0.001 130.366 0.001
202603 0.000 132.262 0.000
202606 0.000 133.527 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Theralase Technologies (FRA:TTX) Overvalued in 2026?

Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued. The current stock price of €0.11 is trading 7% above its estimated GF Value™ of €0.10. GuruFocus considers Theralase Technologies to be Fairly Valued.

Key valuation signals for FRA:TTX:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.10 vs. price of €0.11 (7% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the FRA:TTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Theralase Technologies Business Description

Other Exchanges TLTFF:USATLT:Canada
Address 41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
51GF Score

Get the complete analysis for FRA:TTX

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.10
GF Value